Infectious Diasease Therapeutics Market Overview, Growth, Trends, Analysis, Research Report (2021-2031)

Infectious Diasease Therapeutics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others),  and Geography

  • Report Code : TIPRE00016883
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Infectious Disease Therapeutics Market Size and Share by 2031

Buy Now

The infectious diasease therapeutics market size in 2023 stood at US$ 124.30 billion and is projected to reach US$ 176.13 billion by 2031. The market is expected to register a CAGR of 4.5% during 2023–2031. Rising number of product approvals and launches is likely to remain key trends in the market.

Infectious Diasease Therapeutics Market Analysis

The rising prevalence of infectious diseases in society, the market players have released advanced medicines for the treatment of infectious disorders, the initiatives taken by the government to provide individuals with sophisticated facilities for the treatment of infectious diseases is driving the market.

Infectious Diasease Therapeutics Market Overview

Bacteria, viruses, fungus, and parasites are all creatures that cause infectious diseases. Antibiotics, antivirals, and antiparasitics are some of the medications used to treat infectious disorders. Therapeutics for infectious diseases could act directly on organisms or aid the body's immune system in fighting infections. Infectious diseases include HIV, tuberculosis, malaria, hepatitis, and influenza, among others.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Infectious Diasease Therapeutics Market: Strategic Insights

Infectious Diasease Therapeutics Market

  • CAGR (2023 - 2031)
    4.5%
  • Market Size 2023
    US$ 124.30 Billion
  • Market Size 2031
    US$ 176.13 Billion

Market Dynamics

GROWTH DRIVERS
  • Rising Prevalence of Infectious Disease
  • Increasing Focus on Funding and R&D for Infectious Disease Therapeutics
FUTURE TRENDS
  • Molecular Diagnostics for Infectious Diseases in Personalized Medicine is the Recent Trend Witnessed in the Market
OPPORTUNITIES
  • Growing Opportunities in Developing Nations

Key Players

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Drug Class
  • Anti-viral
  • Anti Bacterial
  • Anti-Fungal
Indication
  • HIV
  • Hepatitis
  • Tuberculosis
  • Influenza
  • HPV
Route of Administration
  • Oral
  • Parenteral
  • Topical
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Infectious Diasease Therapeutics Market Drivers and Opportunities

Increasing Focus on Funding and R&D in Infectious Disease Therapeutics to Favor Market Growth

Research and development (R&D) is a important part of the business of pharmaceutical companies and biopharmaceuticals. R&D allows the companies to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

The table below displays the annual funding for various disease categories and research on the basis of contracts, grants, and other funding mechanisms used across the National Institutes of Health (NIH).

Diseases and Funding

Disease/Research Areas

2019 (US$ Millions)

2020 (US$ Millions)

2021 (US$ Millions)

2022 (US$ Millions)

Emerging Infectious Diseases

 2,950

 4,867

5,069

4,318

Infectious Diseases

6,313

 8,301

8,599

8,019

Sexually Transmitted Infections

 354

 394

404

419

Note: Current conversion rate is considered for the currencies.

Source: Annual Reports and The Insight Partners Analysis

The major projects that the manufacturers have funded:

• In June 2022, GSK plc invested US$ 1.21 billion (£1 billion) over 10 years to expedite research and development (R&D) focused on infectious diseases that disproportionately affect low-income nations. The research will concentrate on new medicines and disruptive vaccines to prevent and treat malaria, tuberculosis, HIV (via ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).

• In March 2022, the Global Fund's COVID-19 Response Mechanism (C19RM) received  a donation of US$ 48.07 million (CAD 60 million) from Canada which was praised by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The new funds was used to offer low- and middle-income countries with vital treatments and diagnostic tests, including medical oxygen, and personal protective equipment (PPE).

Thus, rising focus on R&D and funding is driving the infectious disease therapeutics market growth.

Growing Opportunities in Developing Nations

The rising prevalence of infectious diseases is anticipated to improve sales of infectious disease treatment medications in emerging countries. Because of the lower data requirements and stricter laws, Asia Pacific has emerged as a flexible and business-friendly region. Furthermore, large investments in health research and life science in emerging countries play an important role in supporting cutting-edge technology in developing countries, which in turn encourages the trend towards infectious disease detection and treatment. For example, UNAIDS is calling for a US$ 29 billion investment by 2025 to satisfy the AIDS prevention and treatment needs of low- and middle-income countries. In India, South Korea, Brazil, and Mexico, infectious diseases such as Hepatitis, HAI, HIV, and influenza are prevalent; there is a big patient population; disposable money has increased; healthcare infrastructure has improved; and medical tourism is expanding. Thus, essential infectious disease therapeutics product producers in expanding infectious disease therapeutics markets in these nations should expect profitable prospects in the future.

Infectious Diasease Therapeutics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the infectious diasease therapeutics market analysis are drug class, indication, route of administration, distribution channel.

  • Based on drug class, the infectious diasease therapeutics market is divided into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2023.
  • By indication, the market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest share of the market in 2023.
  • In terms of route of administration, the market is segmented into a oral, parenteral, topical, and others. The oral manufacturers segment held the largest share of the market in 2023.
  • Based on distribution channel, the infectious diasease therapeutics market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2023.

Infectious Diasease Therapeutics Market Share Analysis by Geography

The geographic scope of the infectious diasease therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region.

Infectious Diasease Therapeutics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 124.30 Billion
Market Size by 2031 US$ 176.13 Billion
Global CAGR (2023 - 2031) 4.5%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Drug Class
  • Anti-viral
  • Anti Bacterial
  • Anti-Fungal
By Indication
  • HIV
  • Hepatitis
  • Tuberculosis
  • Influenza
  • HPV
By Route of Administration
  • Oral
  • Parenteral
  • Topical
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • BioCryst Pharmaceuticals Inc
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

    Infectious Diasease Therapeutics Market News and Recent Developments

    The infectious diasease therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the infectious diasease therapeutics market are listed below:

    • Roche launched the first infectious disease tests and cobas omni–Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The cobas omni–Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform. (Source: F. Hoffmann-La Roche Ltd, Press Release, December 2022)

    Infectious Diasease Therapeutics Market Report Coverage and Deliverables

    The “Infectious Diasease Therapeutics Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Infectious diasease therapeutics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Infectious diasease therapeutics market trends as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • infectious diasease therapeutics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the infectious diasease therapeutics market
    • Detailed company profiles
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Drug Class, Indication, Route of Administration, Distribution Channel

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What are the driving factors impacting the infectious diasease therapeutics market?

    Rising prevalence of infectious disease and increasing focus on funding and R&D for infectious disease therapeutics are the factors driving the market.

    What are the future trends of the infectious diasease therapeutics market?

    Rising number of product approvals and launches is likely to act as future trends in the market.

    Which are the leading players operating in the infectious diasease therapeutics market?

    Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc are the leading players operating in the infectious diasease therapeutics market.

    What would be the estimated value of the infectious diasease therapeutics market by 2031?

    The estimated value of the market by 2031 will be US$ 176.17 billion.

    What is the expected CAGR of the infectious diasease therapeutics market?

    The market is estimated to grow at a CAGR of 4.5% during 2023–2031.

    Trends and growth analysis reports related to Pharmaceuticals : READ MORE..